- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 35/00 - Antineoplastic agents
Patent holdings for IPC class A61P 35/00
Total number of patents in this class: 111748
10-year publication summary
|
3541
|
5645
|
7833
|
8552
|
9469
|
10513
|
10714
|
10144
|
9297
|
5276
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| The Regents of the University of California | 20745 |
976 |
| Novartis AG | 10262 |
948 |
| Genentech, Inc. | 4104 |
779 |
| F. Hoffmann-La Roche AG | 7837 |
742 |
| Bristol-myers Squibb Company | 4742 |
724 |
| Dana-Farber Cancer Institute, Inc. | 2664 |
690 |
| Board of Regents, The University of Texas System | 6107 |
636 |
| Memorial Sloan-Kettering Cancer Center | 2043 |
537 |
| Hoffmann-La Roche Inc. | 3793 |
517 |
| The Johns Hopkins University | 5882 |
498 |
| AstraZeneca AB | 2814 |
486 |
| Centre National de La Recherche Scientifique | 11023 |
480 |
| Amgen Inc. | 4427 |
467 |
| Incyte Corporation | 1071 |
458 |
| Merck Patent GmbH | 5728 |
455 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 3001 |
451 |
| Institut National de La Sante et de La Recherche Medicale (inserm) | 3229 |
425 |
| Janssen Biotech, Inc. | 1764 |
401 |
| Inserm (institut National de La Sante et de La Recherche Medicale) | 3335 |
398 |
| Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 775 |
397 |
| Other owners | 100283 |